KRAS and neoplasm: Recent pre-clinical studies evaluated combination partners of BET inhibitors such as phosphatidylinositol-4,5-bisphosphate 3-kinase inhibitors, histone deacetylase inhibitors, or a CD20 monoclonal antibody in different tumor types.31, 32, 33 Here we used the small-molecule BET inhibitor JQ1 alone and in combination with TRAIL or cisplatin in KRAS-mutated NSCLC cell lines, to promote apoptosis in these cells.